06.11.2015 RHÖN-KLINIKUM AG  DE0007042301

DGAP-News: RHÖN-KLINIKUM AG: Interim Report for the Third Quarter: Business Development as Plannes - Second Share Repurchase - Scheme Completed - New Departmental Responsibilities for the Management Board


 
DGAP-News: RHÖN-KLINIKUM AG / Key word(s): Quarter Results/Quarter Results RHÖN-KLINIKUM AG: Interim Report for the Third Quarter: Business Development as Plannes - Second Share Repurchase - Scheme Completed - New Departmental Responsibilities for the Management Board 06.11.2015 / 07:00 --------------------------------------------------------------------- Corporate News RHÖN-KLINIKUM AG Schlossplatz 1 D-97616 Bad Neustadt/Saale www.rhoen-klinikum-ag.com Interim Report for the Third Quarter: - RHÖN-KLINIKUM AG Business Development as Planned - Second Share Repurchase Scheme Completed - New Departmental Responsibilities for the Management Board - 569,978 patients treated - Revenues amount to EUR 832.0 million - EBITDA stands at EUR 117.3 million - Outlook for 2015 remains unchanged: revenues between EUR 1.08 billion and EUR 1.12 billion,EBITDA between EUR 145 million and EUR 155 million Bad Neustadt / Saale, 6th November 2015 RHÖN-KLINIKUM AG's operative business progressed as planned in the first nine months of the current financial year. A total of 569,978 patients were treated in the company's hospitals during this period. Revenues for the period from January up to and including September amounted to EUR 832.0 million and earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at EUR 117.3 million. These financial figures are not directly comparable with those of previous years due to the sale of a total of 43 facilities which was completed during last financial year 2014. Successful Completion of Second Share Repurchase Scheme The second share repurchase scheme ended on 8th October 2015. The public purchase offer was accepted for a total of 6,519,390 RHÖN KLINIKUM shares at a share price of EUR 25.54 which corresponds to approx. 9 % of the total share capital issued on the cut-off date and a volume of approx. EUR 167 million. With its new financial structure the corporate group can now embrace more purposefully the requirements of resource management orientated to capital costs and is therefore in a better position to be able to take advantage of business opportunities for further development. Larger Board of Management, Modified Departmental Responsibilities and Standardised Contractual Terms The company's Board of Management will be enlarged with effect from 1st January 2016. Prof. Dr. Bernd Griewing, spokesperson for the Medical Board and Medical Director of the Neurological Clinic in Bad Neustadt, has been appointed to the executive body by the Supervisory Board as the Chief Medical Officer (CMO) alongside Dr. Martin Siebert (CEO), Jens-Peter Neumann (CFO) and Martin Menger (COO). The departmental responsibilities of the Board of Management have also been modified and the terms of the service agreements of the Board of Management standardised; all the members will now receive a five-year agreement, each starting on 1st January 2016. Outlook We continue to expect revenues of EUR 1.08 billion to EUR 1.12 billion and EBITDA of between EUR 145 million and EUR 155 million for 2015, the first full financial year with the new portfolio structure. As in previous years one-off effects will continue to influence the corporate results during this financial year as well. These positive and negative special influences will occur during the entire financial year 2015, their size is a low two-digit million figure and they will partially cancel each other out. "We are continuing to press ahead with the extensive implementation of our corporate strategy with targeted investments in the building structures and medical equipment of our hospitals, systematically linking medicine and nursing to each other and also realising synergies," CEO Dr. Martin Siebert said. "Our focus on healthcare which is orientated to maximum medical care and has a direct link to universities is also reflected in the new structure of the Board of Management: with a larger Board and modified departmental responsibilities we have now created the preconditions for consistent further development of the larger medical concepts of the future, such as e-health, ensuring high-quality medical care in rural areas and extending medical networks to provide excellent healthcare services further afield. This will benefit our patients, employees and shareholders alike," Siebert continued. ************************************************************************** RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. With ten hospitals in five locations and a total of roughly 5,300 beds we offer affordable cutting-edge medical care with a direct link to universities and research institutes. Our facilities are located in Bad Berka, Bad Neustadt/Saale, Frankfurt (Oder) and Giessen and Marburg. A total of over 15,000 employees work for RHÖN-KLINIKUM AG. Further information is available at: www.rhoen-klinikum-ag.com. Your Contact Persons: RHÖN-KLINIKUM AG Achim Struchholz Head of Corporate Communication Schlossplatz 1 97616 Bad Neustadt / Saale Telephone: + 49 - 9771 65-1327 Facsimile: + 49 - 9771 65-1820 E-Mail: [email protected] Dr. Kai G. Klinger Head of Investor Relations & Group Financing Schlossplatz 1 97616 Bad Neustadt / Saale Telephone: + 49 - 9771 65-1318 Facsimile: + 49 - 9771 99-1736 E-Mail: [email protected] --------------------------------------------------------------------- 06.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: RHÖN-KLINIKUM AG Schlossplatz 1 97616 Bad Neustadt a.d.Saale Germany Phone: +49 (0)9771 - 65-0 Fax: +49 (0)9771 - 97 467 E-mail: [email protected] Internet: www.rhoen-klinikum-ag.com ISIN: DE0007042301 WKN: 704230 Indices: MDAX Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart End of News DGAP News Service --------------------------------------------------------------------- 409759 06.11.2015


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.211,08 1.232,91 1.303,90 1.360,16 1.402,01 1.446,09 1.463,98
EBITDA1,2 97,82 125,54 125,33 80,23 101,16 105,65 105,88
EBITDA-Marge3 8,08 10,18 9,61 5,90 7,22 7,31
EBIT1,4 38,70 64,94 56,80 10,60 30,52 36,11 40,40
EBIT-Marge5 3,20 5,27 4,36 0,78 2,18 2,50 2,76
Jahresüberschuss1 36,74 51,19 44,48 2,46 30,23 26,94 40,17
Netto-Marge6 3,03 4,15 3,41 0,18 2,16 1,86 2,74
Cashflow1,7 80,30 49,50 47,30 113,30 97,50 41,30 109,00
Ergebnis je Aktie8 0,53 0,73 0,65 0,02 0,42 0,38 0,58
Dividende8 0,22 0,29 0,00 0,00 0,00 0,15 0,35
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Rhön-Klinikum
WKN Kurs in € Einschätzung Börsenwert in Mio. €
704230 11,400 Halten 763,37
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
19,00 28,13 0,68 19,49
KBV KCV KUV EV/EBITDA
0,61 7,00 0,52 6,62
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,15 0,00 0,00 05.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 08.08.2024 07.11.2024 28.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,97% 1,46% 14,00% -12,98%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu RHÖN-KLINIKUM AG  ISIN: DE0007042301 können Sie bei EQS abrufen


Pflegeeinrichtungen , 704230 , RHK , XETR:RHK